| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000013366 |
| Receipt No. | R000015393 |
| Official scientific title of the study | Features of responders to Tolvaptan in CKD patients |
| Date of disclosure of the study information | 2014/03/07 |
| Last modified on | 2016/09/08 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Features of responders to Tolvaptan in CKD patients | |
| Title of the study (Brief title) | CKD-FORT study | |
| Region |
|
|
| Condition | |||
| Condition | Chronic kidney disease | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To evaluate the short-term and long-term impact of Tolvaptan in advanced stage CKD patients by observing the efficacy of the drug and other selected parameters. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Others |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Urine output after initiating Tolvaptan |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Inclusion criteria are as follows: CKD 4 and 5 patients with volume overload and insufficient response to loop or other diuretic agents; older than 20 years old; being able to express clear understanding of the purpose of the study; being able to complete a written informed consent.
Patients gender will not be restricted. Informed consent can be obtained by families for those who are not able to write it by themselves. |
|||
| Key exclusion criteria | 1. Previous history of tolvaptan use
2. Contraindication for tolvaptan 3. Unable to take an oral medication 4. Requiring immediate dialysis therapy 5. Pregnant or wish to be pregnant 7. History of major surgery within 60 days 8. History of acute myocardial infarction within 30 days 9. Severe hepatic failure or heart disease 10. Other cases which treating physicians regards as inappropriate for a candidate |
|||
| Target sample size | 75 | |||
| Research contact person | |
| Name of lead principal investigator | Sei Sasaki |
| Organization | Tokyo Medical and Dental University |
| Division name | Department of Nephrology |
| Address | 1-5-45 Yushima Bunkyo-ku Tokyo, Japan |
| TEL | 03-5803-5214 |
| tokado.kid@tmd.ac.jp | |
| Public contact | |
| Name of contact person | Tomokazu Okado |
| Organization | Tokyo Medical and Dental University |
| Division name | Department of Chronic Kidney Disease |
| Address | 1-5-45 Yushima Bunkyo-ku Tokyo, Japan |
| TEL | 03-5803-5214 |
| Homepage URL | http://www.tmd.ac.jp/grad/kid/kid-J.htm |
| tokado.kid@tmd.ac.jp | |
| Sponsor | |
| Institute | Department of Nephrology, Tokyo Medical and Dental University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | none |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | Affiliated hospitals of Tokyo Medical and Dental University Hospital |
| Name of secondary funder(s) | none |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 東京医科歯科大学病院(東京都) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | No other related information |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000015393 |